Neovascular Age-related Macular Degeneration
185
16
34
113
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
45 trials with published results (24%)
Research Maturity
113 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.6%
16 terminated out of 185 trials
87.6%
+1.1% vs benchmark
32%
60 trials in Phase 3/4
40%
45 of 113 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 113 completed trials
Clinical Trials (185)
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Extension Study for the Port Delivery System With Ranibizumab (Portal)
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration